Noncoding RNAs (ncRNAs) include a diverse range of RNA species, including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). MiRNAs, ncRNAs of approximately 19–25 nucleotides in length, are involved in gene expression regulation either via degradation or silencing of the messenger RNAs (mRNAs) and have roles in multiple biological processes, including cell proliferation, differentiation, migration, angiogenesis, and apoptosis. LncRNAs, which are longer than 200 nucleotides, comprise one of the largest and most heterogeneous RNA families. LncRNAs can activate or repress gene expression through various mechanisms, acting alone or in combination with miRNAs and other molecules as part of various pathways. Until recently, most research has focused on individual lncRNA and miRNA functions as regulators, and there is limited available data on ncRNA interactions relating to the tumor growth, metastasis, and therapy of cancer, acting either on mRNA alone or as competing endogenous RNA (ceRNA) networks. Triple-negative breast cancer (TNBC) represents approximately 10%–20% of all breast cancers (BCs) and is highly heterogenous and more aggressive than other types of BC, for which current targeted treatment options include hormonotherapy, PARP inhibitors, and immunotherapy; however, no targeted therapies for TNBC are available, partly because of a lack of predictive biomarkers. With advances in proteomics, new evidence has emerged demonstrating the implications of dysregulation of ncRNAs in TNBC etiology. Here, we review the roles of lncRNAs and miRNAs implicated in TNBC, including their interactions and regulatory networks. Our synthesis provides insight into the mechanisms involved in TNBC progression and has potential to aid the discovery of new diagnostic and therapeutic strategies.

Rationale: Erythema multiforme (EM) is an immune-mediated disease with mucocutaneous localization and plurietiologic determinism. The term “multiforme” refers to the variety of aspects that the lesions can take from patient to patient and during evolution in a single patient. Patient concerns: We have selected 2 cases of small children diagnosed with different etiology of EM to illustrate the importance of a correct and fast diagnosis. Case 1 involves a 2-year-old girl from a rural area who presented with fever and pruritic erythematous papular eruption. The onset of the symptoms was 3 days before presentation with fever and ulcerative lesions on the oral and labial mucosa, followed by the appearance of erythematous macular lesions, with progressive confluence to intense pruritic patches. The 2nd involves a 2-year-old boy with fever, loss of appetite, productive cough, and petechiae. He had corticosensible immune thrombocytopenia from the age of 6 months, with many recurrences. The patient received treatment with ampicillin/sulbactam and symptomatics for an erythemato-pultaceous angina. During the 2nd day of treatment the patient developed an erythematous macular eruption on the face, scalp, trunk, and limbs, with bullae formation. Diagnoses: The 1st patient was diagnosed based on biologic findings: positive inflammatory syndrome, elevated level of anti-Mycoplasma pneumoniae immunoglobulin M antibodies and immunoglobulin E. Histopathologic examination described papillary dermal edema, inflammatory infiltrate, and lymphocyte exocytosis. In the 2nd case, the hemoleucogram identified 12,000/mm3 platelets and the medulogram aspect was normal. Serology for Epstein–Barr virus was negative. The diagnosis was EM secondary to M pneumoniae infection in case 1 and secondary to administration of ampicillin/sulbactam in case 2. Interventions: In both cases, etiopathogenic treatment consisting of steroidal antiinflammatory drugs, antihistamines was administered. Because of specific etiology, the 1st case received antibiotics. Outcomes: The evolution was favorable in 10 to 14 days; the patients were discharged after etiopathogenic treatment consisting of steroidal antiinflammatory drugs, antihistamines, and/or antibiotics. Lessons: Performing a detailed clinical examination, medical history of drug use, infection or general diseases can establish a good diagnosis of EM. Histopathologic examination can help. The treatment is etiologic, pathogenic, and symptomatic. EM usually has a self-limited evolution.

Improvements in early detection of cancer have led to an important decrease in mortality rates of cancer. Given the increased incidence rates and decreased mortality rates, the number of patients surviving cancer is rapidly increasing. Although cancer patients face many physical and psychological symptoms, they also continue to engage in poor health behaviors at rates similar to those of the general-healthy population. The prime example of such unhealthy behavior is smoking. The reports show that smoking rates at the time of diagnosis of cancer vary from 10% to 95%. Our study analyzed how the smoking status influenced the outcome of chemotherapy of 249 patients suffering from various forms of cancer. Our statistical analysis showed that patients who smoked had a significant different response to chemotherapy compared to their nonsmoking peers. This meant that in our sample of 149 cancer suffering patients, individuals who did not smoke had a significant better chance of a partial positive response after chemotherapy compared to patients who smoked regularly. Therefore, tobacco smoking is an adverse prognostic factor associated with a resistance to chemotherapy. These results are important given the fact that cancer patients already face a combination of unpleasant symptoms related to their disease but also from the side effects of their treatment. Uncovering the exact mechanisms through which smoking is affecting the outcome of chemotherapy may help in increasing the quality of life, the symptom burden or the final outcome of chemotherapy.

Background: Pneumonia remains an important cause of morbidity and mortality at pediatric age (estimated by UNICEF at 3 million child deaths per year worldwide). Although the etiology of pneumonia is well known, in many patients the exact pathogen is not identified after routine diagnostic workup. We present three cases with complications. that were diagnosed and treated in our Pneumology Clinic. The aim of this case series is to point out the challenges in diagnosing and managing such diseases in children. The evolution of the three cases was difficult, all children needed ICU care. Cultures collected for all of them were negative, probably secondary to the fact that they received antibiotic treatment at home, before carrying out tests. Yet, after receiving broad-spectrum antibiotics and supportive treatment the evolution was favorable in the end. Conclusion: Despite progresses that were made in the last century concerning the antibiotic treatment in pneumonia there are still cases that develop severe complications that require multidisciplinary approach.

No abstract